Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer

Exelixis, Inc. EXEL announced that it has submitted a supplemental new drug application (sNDA) to the FDA seeking approval for its lead drug, Cabometyx (cabozantinib), in combination with Bristol Myers Squibb’s BMY immune-checkpoint inhibitor Opdivo (nivolumab) for previously untreated renal cell carcinoma (RCC). RCC is the most common type of kidney cancer in adults.